GlobeNewswire

BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
12/11/2026
SUNNYVALE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in [...]
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
12/11/2026
Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company [...]
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
12/11/2026
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated long-term efficacy data for both relutrigine and ulixacaltamide [...]
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
12/11/2026
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 – – STRO-006, ITGB6-targeting ADC, enters clinic with first patient [...]
YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
12/11/2026
FDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001 TAIPEI, Taiwan, Nov. 12, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a [...]
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12/11/2026
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in [...]
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
12/11/2026
Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program The [...]
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
12/11/2026
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart [...]
VitalHub Reports Third Quarter 2026 Results
12/11/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 14% YoY to $107.2 million Total Revenue flat YoY at $31.9 million Adjusted EBITDA⁽¹⁾ up 20% YoY to $8.6 million TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI [...]
Windward Bio Announces Pricing of Initial Public Offering
13/11/2026
BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious [...]
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
13/11/2026
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration TOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that “ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2026
12/11/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - October 2026
12/11/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
12/11/2026
Company Announcement COPENHAGEN, Denmark; November 12, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
12/11/2026
NOVATO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and [...]
Aristocrat Plastic Surgery Expands Access to Preservé Breast Augmentation Under Trainer Dr. Kevin Tehrani, Who Has Performed More Than 5,000 Breast Procedures, Reinforcing Its Position as a Destination for Breast Augmentation in NYC
12/11/2026
New York, NY, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aristocrat Plastic Surgery, a New York-based cosmetic and reconstructive plastic surgery practice, today announced that it is expanding access to Motiva Preservé breast [...]
Serotonin Anti-Aging Centers Founder Puts a Physician-Led Longevity Clinic Inside New York Sports Club
12/11/2026
From Retro Fitness founder Eric Casaburi, Serotonin Active will open on Manhattan's Upper East Side in Q1 2027 for NYSC members and the public alike NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Serotonin Active, the [...]
HerScan CEO CiCi McMullen Featured in Forbes for Leadership in Expanding Breast Health Screenings
12/11/2026
Feature highlights McMullen’s entrepreneurial journey, women’s leadership, and HerScan’s mission to make supplemental screenings more accessible. TAMPA BAY, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- HerScan CEO CiCi [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum